These findings are supported by meta-analyses that demonstrate a favourable effect on LVEF with the use of ACE inhibitors, ARBs, beta-blockers, and MRAs as primary prevention in cancer patients undergoing anthracycline or HER-2 therapies [129,130,131]. Here, ERBB2 is linked to cancer.